The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
My forecast = By close of business Friday, over £1
Its a start :-) Foralumab !!!!
Just gone to Blue :-)
lol......…...……….
Maybe recovering...….
Nibbles really , the SP is tanking yes let’s eat nibbles
BJ and Mr Handjob probably got their lab men on the case now announcement made.
For the first time in a while some small nibbles this afternoon ??????
Agreed guys although seriously struggling to gain any traction at the moment.
Some positive spin from outside the company would be most welcome.
Radio silence still from within the company but I get the feeling something nice is cooking.
Hi Bluebelly,
>> This has more potential than anything else on the market IMHO.
Add Foralumab and you have the perfect combo treatment!!!
Regards,
Also:
We have IND submission 2Q, 2021 for TZLS-501 - Inhaled lung delivery for COVID-19 for Q2 21, another fully human anti IL-6 receptor mAb.
From the same RNS: The Company is accelerating development of anti-Interleukin 6 receptor ("IL6R") mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
This has more potential than anything else on the market IMHO. However it will not be an easy road. PI's will be shaken out at every opportunity. Hold tight and add where you can.
BB
The expert who just spoke on BBC TV said that anti-virals are ineffective once inflammation takes hold. Boris’ headline grabbing goes for completely the wrong target!
It’s Foralumab and SNG every-time for me!!!
Politicians... they probably have BOGOF on the useless Remdesivir.
From RNS 30 March 21:
Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody.
Followed by:
Foralumab is the first monoclonal antibody that can be dosed nasally or orally, due to its ability to effect systemic immunity via the epithelial lining of the nose, respiratory tract and gut.
· The direct rapid delivery of Foralumab to the nasal passage and respiratory tract was shown in a previous study of mild to moderate Covid-19 patients to suppress lung inflammation, as evident from CT scans and reduced systemic markers of inflammation including interleukin-6 and C-reactive protein.
We might be behind in terms of phase 3 is a while away, but this makes it ideal to get fast tracked. This could be the holy grail.
BB
Yes I get the impression that the Indian variant is vaccine-immunity-evasive in a way that the SA variant isn't. Hence the softening up for an enhanced "booster" in autumn, "live with the virus" (can't lockdown forever) and a new focus on cures. The two leading cures in terms of not just incremental but potentially radical reductions in death rates are Synairgen's beta inteferon inhaler and foralumab. He spoke of possible oral intake; well, foralumab can be delivered orally, and synairgen you just sniff. With us ending phase 2 trials (or ended them - any ideas?) and synairgen ending or ended £80m worth of phase 3, I expect both to get a lift out of this.
Yep, we are talking about politicians here.
...comments redacted.
Safety profile is phenomenal
It's coming. When they see the bleedin' obvious.
BB
Interesting announcement from Boris tonight about fast tracking potential treatments - including treatments you can take at home if you test positive or if someone in your household tests positive.
Foralumab anyone?